Amgen said its Kyprolis drug met its primary endpoint in an interim analysis, showing progression-free survival for patients treated with relapsed multiple myeloma.
from WSJ.com: US Business http://ift.tt/1nkpm3J
via IFTTT
from WSJ.com: US Business http://ift.tt/1nkpm3J
via IFTTT
No comments:
Post a Comment